Nutriband Inc.
NTRB Healthcare Biotechnology
Nutriband Inc.’s revenue for fiscal 2026 (year ended January 2026) was $2.0 million, down 4.80% from fiscal 2025. In the quarter to July 2026, revenue fell 29.7%, EPS grew 96.7%, free cash flow grew 55.5% and total debt fell 46.9%, each against the same quarter a year earlier.
Follow NTRB
Nutriband Inc. (NTRB) EV/Sales
As of 16 October 2026, Nutriband Inc. (NTRB) trades at a EV/Sales of 44.7×. Over the past ten years it has ranged from 0.0× (July 2019) to 417× (July 2019); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 24.6× | (37.13%) |
| FY2025 | 39.1× | 299.84% |
| FY2024 | 9.8× | (29.94%) |
| FY2023 | 14.0× | (20.59%) |
| FY2022 | 17.6× | (84.04%) |
| FY2021 | 110× | (45.26%) |
| FY2020 | 201× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jul 2026 | 19.4× | (19.10%) |
| Apr 2026 | 23.9× | (2.77%) |
| Jan 2026 | 24.6× | (26.16%) |
| Oct 2025 | 33.3× | 16.11% |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| OKYO OKYO Pharma Limited Sponsored ADR compare | n/m |
| PDSB PDS Biotechnology Corporation compare | n/m |
| CLLS Cellectis S.A. compare | 0.2× |
| PTHS Pelthos Therapeutics Inc. compare | 2.7× |
| NTRB Nutriband Inc. | 44.7× |
| CRDF Cardiff Oncology, Inc. compare | 57.3× |
| PMN Promis Neurosciences compare | 11,382× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)